Redeye updates its estimates and valuation following Vitec releasing its Q1 2023 report. We judge that notable positives from the report include continued strong sales growth and solid margins. We. | April 24, 2023
Redeye updates its outlook on Hansa Biopharma, anticipating gradual launch support during 2023 and supporting pipeline progress over the next 12 months. We make a negative revision after the recent Q1. | April 21, 2023
Redeye returns with a view on Tesofensine following the positive opinion of the drug as an obesity treatment in Mexico by the technical committee of its regulatory agency. We raise our base case to. | April 19, 2023
Redeye saw a sales performance in the quarter that did not meet our high expectations but still showed a healthy organic growth of 20%. We assess that the 1-2 orders we expected did not materialize in. | April 14, 2023
Redeye provides a research update following the Q2 report published by Newbury yesterday. We make some slight adjustments to our estimates for operational expenditures, investments, and net sales.. | April 13, 2023